Remove 2030 Remove Compounding Remove Documentation
article thumbnail

Establishing quality assurance in personalised preparations

European Pharmaceutical Review

A paper published in Pharmaceutics has proposed how a personalised preparation quality assurance programme can achieve this when these products are developed in compounding laboratories. It requests that compounding laboratories adhering to the programme send samples of it. These are documented and their root cause is sought.

article thumbnail

Healthier Together and philanthropic ventures in tropical disease

European Pharmaceutical Review

A guidance document has been released to support these activities. The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. Did you know, 1.7

Vaccines 110
article thumbnail

Veterinary Medicine Outlook: 5 Changes and Trends Impacting Veterinary Practices

epicur

Implementation of GFI #256 Earlier this year, the FDA finalized regulatory guidance for compounded medications, known as GFI #256. If GFI is affecting your practice’s ability to get compounded medications for office use, partnering with a trusted 503B outsourcing facility can help you eliminate risks of limited ordering.